Howard is one of 2,800 patients in Greater Manchester with COPD taking part in The Salford Lung Study, a ground breaking clinical trial that explores how effective a treatment for COPD is in everyday life.
COPD is an umbrella term that describes respiratory conditions limiting airflow to the lungs. It is the third leading cause of death across the globe and currently affects approximately 329 million people like Howard worldwide.
The Salford Lung Study looks at the effectiveness of a COPD medicine and whether the treatment affects the number of times a patient’s condition flares up or worsens. These are known as exacerbations.
“The first thing you’ve got to realise living with COPD is that you can’t live life at the pace you did before. Occasionally I will move too quickly and get very tight in the chest. The exacerbation of COPD is extremely frightening. Breathing is very difficult.”
What makes the Salford Lung Study unique is that, unlike traditional randomised control trials, the study involves patient’s local GPs, hospitals and pharmacies.